Lorlatinib for advanced ROS1+non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort
Journal article published in 2020 by
N. Girard,
S. Galland Girodet,
M. Duruisseaux,
Avrillon,
B. Roch,
J. Otto,
J. Cadranel,
M. Coudurier,
D. Moro-Sibilot,
T. Egenod,
R. Lamy,
J. Bennouna,
G. Zalcman 
,
C. Ricordel,
J. Tillon
and other authors.
,
C. Ricordel,
J. Tillon
and other authors.
